HMN 2025: How Vancomycin trial reveals no important discount in recurrent C. diff infections

University of Wisconsin–Madison–led researchers report decrease but statistically non-significant recurrence of Clostridioides difficile (C. diff) amongst adults given low-dose oral vancomycin throughout antibiotic remedy.

Antibiotics utilized in hospital settings can disrupt the traditional intestine flora. Although antibiotic resistance stays unusual, C. diff spores can survive antibiotic programs and take over within the absence of competing microbiota. Once allowed to turn into dominant, C. diff is notoriously tough to clear, ceaselessly exhibiting up time and again after remedies.

Previous investigations have discovered alerts that vancomycin is likely to be useful, however with confounding, variable inclusion standards, and unclear outcomes, one thing the present trial had hoped to keep away from.

In the research, “Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection,” published in JAMA Network Open, researchers carried out a Phase II, double-blind, placebo-controlled randomized scientific trial to guage whether or not once-daily 125 mg oral vancomycin can forestall recurrent an infection.

Enrollment comprised 81 adults who had accomplished remedy for C. diff inside the past 180 days and have been initiating systemic antibiotics for non-C. diff indications, recruited between 2018 and mid 2023.

Participants have been enrolled at 4 well being methods: University of Wisconsin–Madison Health (55), Medical College of Wisconsin (18), Henry Ford Hospital (six), and Mayo Clinic (two).

Participants have been randomized 1:1 to oral vancomycin or lactose placebo taken all through the antibiotic course plus 5 extra days. Weekly phone follow-ups captured signs, and stool testing employed two-step toxin assays for confirmed recurrences. Secondary evaluation assessed vancomycin-resistant Enterococcus carriage from stool or perirectal swabs collected at baseline and week eight.

Recurrent C. diff emerged in 17 of 39 contributors receiving vancomycin (43.6%) versus 24 of 42 receiving placebo (57.1%), an absolute distinction of ?13.5 proportion factors (95% CI, ?35.1% to eight.0%; P = .22). Adverse occasions affected 27 contributors in every group, primarily gastrointestinal problems. Eight-week intestine colonization by vancomycin-resistant Enterococcus was detected in 15 of 30 vancomycin recipients (50.0%) and 6 of 25 placebo recipients (24.0%; P = .048).

Investigators initially calculated that roughly 150 contributors could be wanted to offer the trial 80% energy to detect a 20-percentage-point drop in C. diff recurrence. Recruitment stalled at 81. Nearly 40% of otherwise-eligible sufferers declined as a result of they have been already taking prophylactic vancomycin and wouldn’t threat placebo, and a pandemic-related suspension of analysis visits additional slowed accrual.

With simply over half the deliberate pattern, confidence intervals across the main end result have been extensive (–35.1 to eight.0 proportion factors) and the P worth rose to .22, leaving probability as a believable rationalization for the noticed 13.5-point distinction. Authors due to this fact state that the research was underpowered, unable to verify or refute oral vancomycin‘s preventive impact.

© 2025 Science X Network